

## STORAGE, RECONSTITUTION, AND ADMINISTRATION<sup>1</sup>

Please refer to the full Prescribing Information for SHINGRIX for full details.

- Prior to reconstitution, store both the antigen (powder) and adjuvant (liquid) components refrigerated between 2° and 8°C (36° and 46°F). Do not freeze; discard if frozen and protect from light
- After reconstitution, administer immediately or store refrigerated between 2° and 8°C (36° and 46°F) for up to 6 hours. Discard if not used within 6 hours. Do not freeze; discard if frozen

### DO NOT FREEZE


**Vial 1 of 2**  
AS01<sub>z</sub> Adjuvant  
Suspension Component  
(liquid)



**Vial 2 of 2**  
Lyophilized VZV gE  
Antigen Component  
(powder)



**1** Cleanse both vial stoppers. Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the adjuvant suspension component (liquid) by slightly tilting the vial. Vial 1 of 2.



**2** Slowly transfer entire contents of syringe into the lyophilized gE antigen component vial (powder). Vial 2 of 2.



**3** Gently swirl the vial until powder is completely dissolved. **Do not shake vigorously.** The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid.



**4** After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine and administer intramuscularly (IM).



Reconstituted Vaccine

gE=glycoprotein E; VZV=varicella zoster virus.

## HOW SHINGRIX IS SUPPLIED<sup>1</sup>



SHINGRIX is supplied as an outer carton of 1 dose (NDC 58160-819-12) containing:

- Adjuvant Suspension Component (Vial 1 of 2)  
NDC 58160-829-01
- Lyophilized gE Antigen Component (Vial 2 of 2)  
NDC 58160-828-01



SHINGRIX is supplied as an outer carton of 10 doses (NDC 58160-823-11) containing:

- Adjuvant Suspension Component (10 vials)  
NDC 58160-829-03
- Lyophilized gE Antigen Component (10 vials)  
NDC 58160-828-03

## BILLING, CODING, AND INSURANCE

**CPT Code** (Product): **90750**

**CPT Code** (Administration) 1 vaccine administered: **90471**

Each additional vaccine administered during same encounter: **90472**

**ICD-10-CM Code** (Encounter for Immunization): **Z23**

**Administration Modifier for Medicare:** **GY**

**MX Code:** **SKB**

**CVX Code:** **187**



If you have any questions regarding SHINGRIX, call 1-800-772-9292 or visit SHINGRIXHCP.com

### Important Safety Information (cont'd)

- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see Important Safety Information throughout and accompanying full Prescribing Information, also available at SHINGRIXHCP.com.

Learn more at SHINGRIXHCP.com



Trademarks owned or licensed by GSK.



©2023 GSK or licensor.  
SGXLBND230003 March 2023  
Produced in USA. 0002-0022-66

## IF YOU COULD PREVENT SHINGLES, WHY WOULDN'T YOU?



Not an actual patient.

Start with a strong recommendation today for appropriate patients

### Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

### Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

Please see Important Safety Information throughout and accompanying full Prescribing Information, also available at SHINGRIXHCP.com.



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

## UNDERSTANDING SHINGLES & AGING

- 99% of people ≥50 years old have had chickenpox, so the virus that causes shingles is already inside their body<sup>3,4</sup>
- In 1 out of 3 people, the dormant virus reactivates and causes shingles<sup>4</sup>
- As immunity against the virus decreases with age, the risk of reactivation increases<sup>5,6</sup>

## WHEN TO RECOMMEND SHINGRIX

- Unlike seasonal vaccines, the SHINGRIX series can be recommended at any time of the year<sup>2</sup>
- The best time to recommend SHINGRIX is any time you are meeting with your adult patients in person or virtually

## GETTING YOUR PATIENTS VACCINATED ANY TIME OF YEAR

### Optimizing the SHINGRIX Referral Process With 4 Simple Steps:

#### 1. Provide a strong recommendation

A strong recommendation can increase the likelihood your patient takes action to get vaccinated, so it's important to make it clear that getting SHINGRIX is the best way to prevent shingles.<sup>1,7</sup>

#### 2. Write an eScript for SHINGRIX

The CDC suggests providing a prescription with your vaccine referral. This can reinforce your recommendation and motivate patients to follow through on receiving their first dose of SHINGRIX.<sup>7</sup>

#### 3. Discuss what to expect with patients

Because SHINGRIX is a 2-dose series, it's important to set expectations, so walk patients through the dosing, administration, and common side effects of SHINGRIX, and emphasize the importance of getting both doses.<sup>1</sup>

#### 4. Follow up with each patient

Following up with patients about their series completion during their next office visit helps to reinforce the urgency of being protected from shingles.<sup>7</sup>

CDC=Centers for Disease Control and Prevention.

### Important Safety Information (cont'd)

- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

Please see Important Safety Information throughout and accompanying full Prescribing Information, also available at [SHINGRIXHCP.com](http://SHINGRIXHCP.com).



## PATIENT ENGAGEMENT

### Topics to discuss with your adult patients

Inform patients of the potential benefits and risks of immunization with SHINGRIX.

**Shingles Disease Risk** Talk about the risk of shingles for those who have had chickenpox.<sup>4</sup>

**Efficacy** SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.<sup>1,\*</sup>

**Safety and Tolerability** The local and general adverse reactions seen with SHINGRIX had a median duration of 2 to 3 days.<sup>1</sup>

**What to Expect** Your patient may experience side effects after receiving SHINGRIX. In clinical trials, the most common side effects were pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach.<sup>1</sup>

\*Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as subjects who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.<sup>1,8</sup>

### Important Safety Information (cont'd)

- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)

**References:** 1. Prescribing Information for SHINGRIX. 2. Berlinberg EJ, et al. *J Clin Virol*. 2020 May; 126: 104306. doi:10.1016/j.jcv.2020.104306 3. Kilgore PE, et al. *J Med Virol*. 2003;70 (suppl 1):S111-S118. 4. CDC. *MMWR*. 2008;57 (RR-5):1-30. 5. Levin MJ. *Curr Opin Immunol*. 2012;24(4):494-500. 6. Weinberg A, et al. *J Infect Dis*. 2010;201(7):1024-1030. 7. CDC. Vaccine referral: a series on standards for adult immunization practice. Updated May 2016. Accessed August 8, 2022. <https://www.cdc.gov/vaccines/hcp/adults/downloads/standards-immz-practice-referral.pdf> 8. Data on file. Study 113077 (NCT01165229). GSK Study Register. Study entry at: <https://www.gsk-studyregister.com/en/trial-details/?id=113077> 9. Data on file, GSK. 10. Kirchhoff SM. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022;1-3. Accessed November 16, 2022. <https://crsreports.congress.gov/product/pdf/IF/IF12203> 11. Managed Markets Insight & Technology, LLC, Database as of October 2022.

## PATIENT ENGAGEMENT (CONT'D)

Shingles can strike your adult patients at any time of the year, so strongly recommend SHINGRIX<sup>2</sup>

### 2-DOSE SERIES

SHINGRIX is a 2-dose series, with the second dose given 2 to 6 months after the first dose. It is important to receive both doses. The efficacy results of SHINGRIX were demonstrated in clinical trials when administered as a 2-dose series.<sup>1</sup>

### DOSING SCHEDULE



RECOMMEND WITH CERTAINTY – SHINGRIX IS \$0 FOR NEARLY ALL PATIENTS 50 AND OLDER<sup>9-11,\*</sup>

For your patients with commercial insurance plans:

More than 9 out of 10 are covered, with average copays just [\$4] or less.<sup>9,11</sup>

[95%] of commercial patients pay \$0 for SHINGRIX.<sup>9,11</sup>

For your Medicare Part D patients:

Great coverage is now even better: Due to the Inflation Reduction Act, all Medicare Part D patients can now get SHINGRIX for \$0 through their pharmacy.<sup>9,10</sup>

\*Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.

<sup>1</sup>SOURCE: Managed Markets Insight & Technology, LLC, Database as of [October 2022]. Coverage represents access to reimbursement from a health plan with restrictions appropriate to the Advisory Committee on Immunization Practices (ACIP) recommendation(s) and/or prescribing information. Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives.

### Important Safety Information (cont'd)

- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women